HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Zydus Lifesciences completes $166 million Assertio acquisition
Jun-17-2026

Zydus Lifesciences has completed acquisition of Assertio Holdings Inc. (Assertio) for a total consideration of $166.33 million. The acquisition has been executed through Zara Merger Sub Inc. (Zara), a step down wholly owned acquisition subsidiary of the company. Post this acquisition, Zara has been merged with and into Assertio. Further, Assertio has become a wholly owned subsidiary of the company. The common stocks of Assertio are no longer listed or traded on the Nasdaq Global Market.

Assertio is a U.S. based specialty oncology pharmaceutical company with established commercial capability of marketing and distribution of differentiated oncology products. Assertio’s product ROLVEDON (eflapegrastim-xnst) is approved as Biologics License Application (BLA) by USFDA for long-acting G-CSF biologic for the prevention of febrile neutropenia in adult cancer parents receiving myelosuppressive chemotherapy. ROLVEDON is administered once per chemotherapy cycle in the oncology supportive care market. Assertio is headquartered in Lake Forest, Illinois.

Zydus Lifesciences (formerly known as Cadila Healthcare) operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

  RELATED NEWS >>